AstraZeneca (AZN) said Friday that results from its phase 3 trial showed its bladder cancer treatment candidate, Imfinzi, improved event-free survival and overall survival in patients with muscle-invasive bladder cancer.

The benefits were observed regardless of whether patients achieved a pathologic complete response, according to the company.

Patients in the study were treated with four cycles of Imfinzi combined with chemotherapy before undergoing bladder removal surgery, followed by eight cycles of Imfinzi monotherapy.

The analysis showed that Imfinzi improved both event-free and overall survival compared to chemotherapy and surgery alone, benefiting patients regardless of whether they achieved a pathologic complete response.

The regimen reduced the risk of disease progression, recurrence, failure to undergo surgery, and death, as well as the risk of death from bladder cancer, according to the company.

AstraZeneca said the treatment with the trial met the primary endpoint of event-free survival and the secondary endpoint of overall survival.

Price: 74.15, Change: -0.30, Percent Change: -0.40